Bayer AG's reported some encouraging third quarter developments in its consumer health business, including a return to OTC status for some brands in China. But much more will be needed to have confidence the business is on the way up.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?